South Korea Antibody Drug Conjugates Market Size & Outlook
South Korea antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
South Korea antibody drug conjugates market highlights
- The South Korea antibody drug conjugates market generated a revenue of USD 54.0 million in 2021 and is expected to reach USD 237.2 million by 2030.
- The South Korea market is expected to grow at a CAGR of 17.9% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 54.0 million |
| Market revenue in 2030 | USD 237.2 million |
| Growth rate | 17.9% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, South Korea accounted for 0.9% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 863.8 million by 2030.
Breast cancer was the largest segment with a revenue share of 52.96% in 2021. Horizon Databook has segmented the South Korea antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
South Korean pharmaceutical company Alteogen offers cutting-edge programs for the development of ADC drugs. It currently has an ADC drug (ALT-P7) for breast/gastric cancer, which completed phase 1 trial and demonstrated high tolerability and disease control rate in May 2020. ALT-Q5 is indicated for ovarian cancer and is in the preclinical phase.
Other companies are forming research collaborations to advance the development of ADC drugs in South Korea. For instance, in January 2021, Pharm Abcine Inc., a clinical-stage biotechnology company focused on the development of human antibody therapeutics, entered into a research collaboration with South Korean company Lego Chem Bio Sciences, Inc., which is focused on R&D in ADCs.
Under this agreement, Pharm Abcine will provide Lego Chem Bio Sciences its preclinical drug PMC-403, for combination research on LCB’s proprietary ADC technology platform. As per the World Cancer Research Fund, South Korea had the highest prevalence of stomach cancer in the world in 2018. Kadcyla and Adectris are the most commonly used ADCs.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Korea antibody drug conjugates market size, by application, 2018-2030 (US$M)
South Korea Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
